Skip to playerSkip to main content
  • 9 hours ago
Zimbabwe, one of Southern Africa’s hardest‑hit countries, is taking a bold step in HIV prevention. The nation has now joined Zambia, Kenya and Eswatini in deploying Lenacapavir — an injection taken just twice a year to help protect communities most at risk.

Category

🗞
News
Transcript
00:00A 42 year old sex worker is among many Zimbabweans at risk of HIV who are eagerly waiting for Lena
00:08Kapavelle, the new twice AA injectable prevention drug.
00:12The country received its first shipment from the United States earlier this month, marking a first step in the fight
00:20against HIV.
00:42With an estimated 1.3 million people living with HIV, Zimbabwe remains one of the country's hardest hit by HIV.
00:51Health authorities say Lena Kapavelle could be a crucial new tool in reducing fresh infections, especially among groups that continue
01:02to face high vulnerability.
01:05New HIV infections continue to occur, especially among adolescent girls and young women and other populations at increased risk.
01:17These terrors are something important. Prevention must fit into real life.
01:25Even as the United States scales back some of its health support, Lena Kapavelle, also known as LEN, stands out
01:33as one of Washington's most impactful ongoing contributions to Zimbabwe and other African countries.
01:41AIDS has plans to support access to LEN for about 271,000 Zimbabweans over the next three years.
01:50This could prevent 9,000 new HIV infections, which is critical to controlling the HIV epidemic in Zimbabwe.
01:59HIV activists say the drug's success will also depend on ensuring that sex workers and other vulnerable groups understand how
02:10it works, especially those with limited access to clear health information.
02:17They don't know the difference between PrEP and ART. So with this injectable injection, we are very happy. And we
02:27applaud our country for recognizing the sex workers. And we applaud our country and the Minister of Health.
02:33NOPE THAT WOULD
02:40PLUS
02:41You
Comments

Recommended